An observational study in STEMI - ST Elevation Myocardial Infarction and CAD, sponsored by Corindus Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by Corindus Inc. (part of Siemens Healthineers) · Observational
Among 82 studies in ST Elevation Myocardial Infarction with a site in United States — 5 open to participants now, 11 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · United States.
Among the 82 studies in ST Elevation Myocardial Infarction with a site in United States, this one is the 26th largest by enrollment of the 27 observational ones that give a count, is one of 5 that started in 2020, is one of 27 observational ones, and was the 60th registered.
851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →5 of the 82 studies in ST Elevation Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
TherOx · Sites in United States
Ages 18–80
Nabeel Hamzeh · Sites in United States
Ages 18+ · Healthy volunteers
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
Life Recovery Systems · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 9 · Phase 4 8
First in 2003; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 100 across the 55 interventional studies, 324 across the 27 observational. Of the 59 that completed or were terminated, 26 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 82 have an industry lead sponsor. The 10 most frequent:
This study is registered under Corindus Inc., one of the names counted as Siemens Healthineers. Under that name alone:
Corindus Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Siemens Healthineers has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
3 of the studies in ST Elevation Myocardial Infarction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05800951Henry Ford Health SystemCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock | 2026-12-31 |
| NCT06438315TherOxSuperSaturated Oxygen Comprehensive Observational Registry | 2027-03 |
| NCT05284747AmgenEVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | 2027-05-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in ST Elevation Myocardial Infarction with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).
This is a prospective, post-market, single-arm, multi-center, observational study to evaluate the performance of the CorPath GRX System during robotic-PCI for acute ST elevation myocardial infarction (STEMI).
Subjects with a clinical indication of STEMI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cardiogenic shock
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with a clinical indication of STEMI.
Device: Robotic-PCI (CorPath GRX System)
Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
Time from Catheterization Lab Arrival to Device Activation (CLADA) by CorPath GRX System.
Time measured from arrival to Cath Lab to device activation by CorPath GRX System.
Time frame: Procedure
Freedom from MACE events
Completion of the STEMI procedure without in-hospital major adverse cardiovascular event MACE). MACE is defined as cardiac death, clinically driven target vessel revascularization (TVR) by repeat PCI, surgical bypass for any segment of the target vessel or stent thrombosis.
Time frame: 72-hours
First Medical Contact (FMC) to device activation time
Time at which first patient evaluation.
Time frame: Procedure
Access to device activation
Time measured from access sheath insertion to device activation by CorPath GRX System.
Time frame: Procedure
Access to wire time
Defined as time measured from sheath insertion to crossing the lesion with the coronary guidewire.
Time frame: Procedure
Overall procedure time
Defined as the time measured from sheath insertion to removal of the last device used to treat the culprit lesion.
Time frame: Procedure
Fluoroscopy time
Total fluoroscopy time (min.) utilized during the procedure as recorded by the Imaging System.
Time frame: Procedure
Patient radiation exposure
DAP (dose-area-product) and AK (air kerma) as recorded during the procedure.
Time frame: Procedure
Contrast fluid volume
Total contrast volume (mL/cc) used during the procedure.
Time frame: Procedure
Conversion to manual (Binary)
Conversion from robotic technique to manual technique due to inability to successfully wire lesion or deliver first device.
Time frame: Procedure
Technical success
Completion of the PCI procedure entirely robotically or with partial manual assistance.
Time frame: Procedure
Serious adverse events
All Serious Adverse Events (SAEs) from the start of the CorPath GRX procedure until the end of the study will be summarized.
Time frame: 72-hours
Plan to share: Undecided — Data will be available 12 months after study completion.
Ran from Sep 2020 to primary completion in Nov 2020, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →